Source: International Congress 2017 – Asthma: mechanisms and treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Bjermer (Lund, Sweden). Clinically meaningful improvements with reslizumab in patient-reported outcomes and lung function in a sub-population defined by the EU indication with =3 exacerbations. 4687

Member's Comments

No comment yet.

Related content which might interest you: Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 FEV6: a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Long-term outcome following first clinically important deterioration in COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Beclometasone diproprionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 COPD related fatigue (COPD-RF) as a patient centred outcome tool in COPD: Various predictors and its correlation with other outcome parameters Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Examination of variations in responder rates in COPD clinical trial outcomes Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Association between patient-reported outcomes and exercise test outcomes in patients with COPD. Source: Virtual Congress 2020 – New insights into determinants of patient-reported outcomes in chronic respiratory diseases Year: 2020 Economic and quality of life consequences of clinically important deterioration in patients with COPD: results from the TORCH study Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 Short physical performance battery as a predictor of adverse outcomes following hospitalisation for an acute exacerbation of COPD Source: International Congress 2016 – Management of dyspnoea and exacerbations in chronic lung diseases Year: 2016 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy of standard rehabilitation in COPD outpatients with comorbidities Source: Eur Respir J 2010; 36: 1042-1048 Year: 2010 Differences in proxy-reported and patient-reported outcomes: Assessing problematic activities of daily life in patients with COPD Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 Do cardiac biomarkers predict long-term outcomes from exacerbations of COPD? Source: International Congress 2017 – Highlights on clinical problems in COPD Year: 2017 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 PROMising developments in IPF patient-reported outcome measures Source: Eur Respir J, 59 (1) 2102312; 10.1183/13993003.02312-2021 Year: 2022 Are spirometric criteria good predictors of longitudinal outcomes in COPD patients without taking chronic respiratory symptoms into account? Results from ECRHS Source: Annual Congress 2008 - Environmental risk factors for respiratory symptoms and COPD Year: 2008 Cardiac biomarkers and long-term outcomes of exacerbations of COPD: a long-term follow-up of two cohorts Source: ERJ Open Res, 7 (1) 00531-2020; 10.1183/23120541.00531-2020 Year: 2021 Reduction in clinically important deterioration in COPD with aclidinium/formoterol Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015